TRPA1
≈ 6 min read
Names in other languages
- DeutschTRPA1
- EnglishTRPA1
- FrançaisTRPA1
- ItalianoTRPA1
- 日本語TRPA1
- NederlandsTRPA1
- srnTRPA1
- 中文TRPA1
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Transient receptor potential cation channel, subfamily A, member 1, also known as transient receptor potential ankyrin 1, TRPA1, or The Mustard and Wasabi Receptor, is a protein that in humans is encoded by the TRPA1 (and in mice and rats by the Trpa1) gene. TRPA1 is an ion channel located on the plasma membrane of many human and animal cells. This ion channel is best known as a sensor for pain, cold and itch in humans and other mammals, as well as a sensor for environmental irritants giving rise to other protective responses (tears, airway resistance, and cough).
Transient receptor potential cation channel, subfamily A, member 1, also known as transient receptor potential ankyrin 1, TRPA1, or The Mustard and Wasabi Receptor, is a protein that in humans is encoded by the TRPA1 (and in mice and rats by the Trpa1) gene. TRPA1 is an ion channel located on the plasma membrane of many human and animal cells. This ion channel is best known as a sensor for pain, cold and itch in humans and other mammals, as well as a sensor for environmental irritants giving rise to other protective responses (tears, airway resistance, and cough).
Clinical significance
In 2008, it was observed that caffeine suppresses activity of human TRPA1, but it was found that mouse TRPA1 channels expressed in sensory neurons cause an aversion to drinking caffeine-containing water, suggesting that the TRPA1 channels mediate the perception of caffeine. TRPA1 has also been implicated in airway irritation by cigarette smoke, cleaning supplies and in the skin irritation experienced by some smokers trying to quit by using nicotine replacement therapies such as inhalers, sprays, or patches. A missense mutation of TRPA1 was found to be the cause of a hereditary episodic pain syndrome. A family from Colombia suffers from debilitating upper-body pain starting in infancy that is usually triggered by fasting or fatigue (illness, cold temperature, and physical exertion being contributory factors). A gain-of-function mutation in the fourth transmembrane domain causes the channel to be overly sensitive to pharmacological activation. Metabolites of paracetamol (acetaminophen) have been demonstrated to bind to the TRPA1 receptors, which may desensitize the receptors in the way capsaicin does in the spinal cord of mice, causing an antinociceptive effect. This is suggested as the antinociceptive mechanism for paracetamol. Oxalate, a metabolite of an anti cancer drug oxaliplatin, has been demonstrated to inhibit prolyl hydroxylase, which endows cold-insensitive human TRPA1 with pseudo cold sensitivity (via reactive oxygen generation from mitochondria). This may cause a characteristic side-effect of oxaliplatin (cold-triggered acute peripheral neuropathy). Although several nonelectrophilic agents such as thymol and menthol have been reported as TRPA1 agonists, most of the known activators are electrophilic chemicals that have been shown to activate the TRPA1 receptor via the formation of a reversible covalent bond with cysteine residues present in the ion channel. Another example of a nonelectrophilic agent is the anesthetic propofol, which is known to cause pain on injection into a vein, a side effect attributed to TRPV1 and TRPA1 activation. A dibenz[b,f][1,4]oxazepine derivative substituted by a carboxylic methyl ester at position 10 has been reported to be a potent nonelectrophilic (thiol-unreactive) TRPA1 agonist (EC 50 = 0.05 nM), while dibenzoxazepine (CR 'gas', 0.3 nM) itself, as well as several other tear gases (CN (30 nM), CS (0.9 nM), CA (10 nM) 'gases') were found to be thiol-reactive TRPA1 agonists. This study found that chemical reactivity with thiols in combination with lipophilicity enabling membrane permeation result in a potent TRPA1 agonistic effect, but thiol adduct formation is neither sufficient nor necessary for TRPA1 activation. The pyrimidine PF-4840154 is a potent, non-covalent activator of both the human (EC 50 = 23 nM) and rat (EC 50 = 97 nM) TRPA1 channels. This compound elicits nociception in a mouse model through TRPA1 activation. Furthermore, PF-4840154 is superior to allyl isothiocyanate, the pungent component of mustard oil, for screening purposes. Other TRPA1 channel activators include JT-010 and ASP-7663, while channel blockers include A-967079, HC-030031 and AM-0902. The eicosanoids formed in the ALOX12 (i.e. arachidonate-12-lipoxygnease) pathway of arachidonic acid metabolism, 12S-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (i.e. 12S-HpETE; see 12-Hydroxyeicosatetraenoic acid) and the hepoxilins (Hx), HxA3 (i.e. 8R/S-hydroxy-11,12-oxido-5Z,9E,14Z-eicosatrienoic acid) and HxB3 (i.e. 10R/S-hydroxy-11,12-oxido-5Z,8Z,14Z-eicosatrienoic acid) (see Hepoxilin#Pain perception) directly activate TRPA1 and thereby contribute to the hyperalgesia and tactile allodynia responses of mice to skin inflammation. In this animal model of pain perception, the hepoxilins are released in the spinal cord directly activate TRPA (and also TRPV1) receptors to augment the perception of pain. 12S-HpETE, which is the direct precursor to HxA3 and HxB3 in the ALOX12 pathway, may act only after being converted to these hepoxilins. The epoxide, 5,6-epoxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-EET) made by the metabolism of arachidonic acid by any one of several cytochrome P450 enzymes (see Epoxyeicosatrienoic acid) likewise directly activates TRPA1 to amplify pain perception. Studies with mice, guinea pigs, and human tissues indicate that another arachidonic acid metabolite, Prostaglandin E2, operates through its prostaglandin EP3 G protein coupled receptor to trigger cough responses. Its mechanism of action does not appear to involve direct binding to TRPA1 but rather the indirect activation and/or sensitization of TRPA1 as well as TRPV1 receptors. Genetic polymorphism in the EP3 receptor (rs11209716 ), has been associated with ACE inhibitor-induce cough in humans. More recently, a peptide toxin termed the wasabi receptor toxin from the Australian black rock scorpion (Urodacus manicatus) was discovered; it was shown to bind TRPA1 non-covalently in the same region as electrophiles and act as a gating modifier toxin for the receptor, stabilizing the channel in an open conformation. Examples of TRPA1 agonists include: 2-Arachidonoylglycerol 4-Oxo-2-nonenal 12S-Hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic acid Allicin Allyl isothiocyanate Anandamide ASP-7663 Cannabichromene Cannabidiol Cannabidiolic acid Cannabidivarin Cannabigerol Cannabigerolic acid Cannabigerovarin Cinnamaldehyde 4,5-Epoxyeicosatrienoic acid Gingerol Hepoxilins A3 and B3 Icilin N-Arachidonoyl dopamine Palmitoylethanolamide PF-4840154 Polygodial Propofol Tetrahydrocannabivarin acid Tetrahydrocannabivarin
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378357650 under CC BY-SA 4.0; modifications have been made.